Bupropion sustained release for pregnant smokers: a randomized, placebo-controlled trial

Tatiana N. Nanovskaya, Cheryl Oncken, Valentina M. Fokina, Richard S. Feinn, Shannon M. Clark, Holly West, Sunil K. Jain, Mahmoud S. Ahmed, Gary D V Hankins

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Background Bupropion is used to treat depression during pregnancy. However, its usefulness as a smoking cessation aid for pregnant women is not fully known. Objective The objective of the study was to evaluate the preliminary efficacy of bupropion sustained release for smoking cessation during pregnancy. Study Design We conducted a randomized, prospective, double-blind, placebo-controlled, pilot trial. Pregnant women who smoked daily received individualized behavior counseling and were randomly assigned to a 12 week, twice-a-day treatment with 150 mg bupropion sustained release or placebo. The primary study objectives were to determine whether bupropion sustained release reduces nicotine withdrawal symptoms on the quit date and during the treatment period compared with placebo and whether it increases 7 day point prevalence abstinence at the end of the treatment period and at the end of pregnancy. Results Subjects in the bupropion (n = 30) and placebo (n = 35) groups were comparable in age, smoking history, number of daily smoked cigarettes, and nicotine dependence. After controlling for maternal age and race, bupropion sustained release reduced cigarette cravings (1.5 ± 1.1 vs 2.1 ± 1.2, P = .02) and total nicotine withdrawal symptoms (3.8 ± 4.3 vs 5.4 ± 5.1, P = .028) during the treatment period. Administration of bupropion sustained release reduced tobacco exposure, as determined by levels of carbon monoxide in exhaled air (7.4 ± 6.4 vs 9.1 ± 5.8, P = .053) and concentrations of cotinine in urine (348 ± 384 ng/mL vs 831 ± 727 ng/mL, P = .007) and increased overall abstinence rates during treatment (19% vs 2%, P = .003). However, there was no significant difference in 7 day point prevalence abstinence rates between the 2 groups at the end of medication treatment (17% vs 3%, P = .087) and at the end of pregnancy (10% vs 3%, P = .328). Conclusion Individual smoking cessation counseling along with the twice-daily use of 150 mg bupropion sustained release increased smoking cessation rates and reduced cravings and total nicotine withdrawal symptoms during the treatment period. However, there was no significant difference in abstinence rates between groups at the end of medication treatment and at the end of pregnancy, likely because of the small sample size. A larger study is needed to confirm these findings and to examine the potential benefit/ risk ratio of bupropion sustained release for smoking cessation during pregnancy.

Original languageEnglish (US)
Pages (from-to)420.e1-420.e9
JournalAmerican journal of obstetrics and gynecology
Volume216
Issue number4
DOIs
StatePublished - Apr 1 2017

Keywords

  • bupropion sustained release
  • pregnancy
  • smoking cessation

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Bupropion sustained release for pregnant smokers: a randomized, placebo-controlled trial'. Together they form a unique fingerprint.

Cite this